Evoke Pharma is a pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. Co. is focused on developing its primary product, Gimoti (metoclopramide) nasal spray. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide providing delivery by nasal spray administration. Co. is party to a commercial services agreement with Eversana Life Science Services, LLC, or Eversana, pursuant to which Eversana commercializes and distributes Gimoti in the U.S. The EVOK stock yearly return is shown above.
The yearly return on the EVOK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EVOK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|